Universität zu Köln

Bitzer, J., Romer, T. and Lopes da Silva Filho, A. (2017). The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review. Eur. J. Contracept. Reprod. Health Care, 22 (3). S. 172 - 183. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1473-0782

Full text not available from this repository.

Abstract

Introduction: Hyperandrogenism affects approximately 10-20% of women of reproductive age. Hyperandrogenic skin symptoms such as hirsutism, acne, seborrhea and alopecia are associated with significant quality of life and psychological impairment. Women with abnormalities in androgen metabolism may have accompanying anovulation and/or polycystic ovary syndrome (PCOS), both of which have reproductive and metabolic implications if left untreated. Cyproterone acetate (CPA), combined with ethinylestradiol (EE), is indicated for the treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhea) and/or hirsutism, in women of reproductive age. Objective: To review the data on the efficacy and safety of CPA 2 mg/EE 35 mu g for the treatment of hyperandrogenic skin symptoms in women. Methods: A non-systematic narrative review based on a literature search of the PubMed database. Results: Seventy-eight studies were identified. The majority of sufficiently powered studies show a high efficacy of CPA 2 mg/EE 35 mu g in the treatment of severe acne and hirsutism. Studies show that therapeutic response in women with hirsutism requires a long-term approach and that hyperandrogenic skin symptoms in patients with PCOS are efficiently treated. Additional benefits include cycle control and, in some women, improvement in mood and perception of body image. Safety and tolerability data are summarized by the pharmacovigilance risk assessment committee (PRAC) of the European Medicine's Agency's (EMA). Conclusions: This review provides a comprehensive overview about the efficacy of CPA 2mg/EE 35g in the treatment of hyperandrogenic skin symptoms, thus allowing both health care professionals and women to balance the risks and benefits of treatment based on evidence.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Bitzer, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Romer, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lopes da Silva Filho, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-246128
DOI:	10.1080/13625187.2017.1317339
Journal or Publication Title:	Eur. J. Contracept. Reprod. Health Care
Volume:	22
Number:	3
Page Range:	S. 172 - 183
Date:	2017
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1473-0782
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language POLYCYSTIC-OVARY-SYNDROME; ORAL-CONTRACEPTIVE PILLS; LONG-TERM TREATMENT; ETHINYL-ESTRADIOL; CLINICAL-EFFICACY; ADOLESCENT GIRLS; HORMONE AGONIST; DIANE 35; PLUS FINASTERIDE; SEVERE HIRSUTISM Multiple languages Public, Environmental & Occupational Health; Obstetrics & Gynecology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/24612